Animal models of inflammatory myopathy

Current Rheumatology Reports

Volumn 14, Issue 3, 2012, Pages 257-263

  Ascherman, Dana P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Endoplasmic reticulum stress (ER stress); Idiopathic inflammatory myopathy (IIM); Inclusion body myositis (IBM); Innate immunity; Major histocompatibility complex I (MHC I); Myositis

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CHEMOKINE RECEPTOR CCR5; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

5' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ARTICLE; CAENORHABDITIS ELEGANS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; DERMATOMYOSITIS; ENDOPLASMIC RETICULUM STRESS; HISTOPATHOLOGY; INCLUSION BODY MYOSITIS; INNATE IMMUNITY; JUVENILE DERMATOMYOSITIS; LYMPHOCYTIC INFILTRATION; MUSCLE WEAKNESS; MYOSITIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; GENETIC PREDISPOSITION TO DISEASE; MYOSITIS; MYOSITIS, INCLUSION BODY; VIRUS DISEASES;

EID: 84860766106     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0245-7     Document Type: Article

References (28)

1. Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008;21:473-94.
2. Morrison TE, Fraser RJ, Smith PN, Mahalingam S, Heise MT. Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J Virol. 2007;81:5132-43. (Pubitemid 46744424)
3. Sandager MM, Nugent JL, Schulz WL, Messner RP, Tam PE. Interactions between multiple genetic determinants in the 5'UTR and VP1 capsid control pathogenesis of chronic post-viral myopathy caused by coxsackievirus B1. Virology. 2008;372:35-47. (Pubitemid 351215464)
4. Andersson J, Englund P, Sunnemark D, Dahlstedt A, Westerblad H, Nennesmo I, Orn A, Lundberg IE. CBA/J mice infected with Trypanosoma cruzi: an experimental model for inflammatory myopathies. Muscle Nerve. 2003;27:442-8. (Pubitemid 36397062)
5. Paciello O, Wojcik S, Gradoni L, Oliva G, Trapani F, Iovane V, Politano L, Papparella S. Syrian hamster infected with Leishmania infantum: a new experimental model for inflammatory myopathies. Muscle Nerve. 2010;41:355-61.
6. • Ohyanagi N, Ishido M, Suzuki F, Kaneko K, Kubota T, Miyasaka N, Nanki T. Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo. Arthritis Rheum. 2009;60:3118-27. Although it was performed in a mixed model of dysferlinopathy and antigeninduced myositis, this study demonstrates the therapeutic potential of immune deviation mediated by retinoids.
7. Leite PE, Lagrota-Candido J, Moraes L, D'Elia L, Pinheiro DF, da Silva RF, Yamasaki EN, Quirico-Santos T. Nicotinic acetylcholine receptor activation reduces skeletal muscle inflammation of mdx mice. J Neuroimmunol. 2010;227:44-51.
8. HuizingM, KrasnewichDM. Hereditary inclusion body myopathy: a decade of progress. Biochim Biophys Acta. 2009;1792:881-7.
9. Rebolledo DL, Minniti AN, Grez PM, Fadic R, Kohn R, Inestrosa NC. Inclusion body myositis: a view from the Caenorhabditis elegans muscle. Mol Neurobiol. 2008;38:178-98.
10. Rebolledo DL, Aldunate R, Kohn R, Neira I, Minniti AN, Inestrosa NC. Copper reduces Abeta oligomeric species and ameliorates neuromuscular synaptic defects in a C. elegans model of inclusion body myositis. J Neurosci. 2011;31:10149-58.
11. Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A. 2002;99:6334-9. (Pubitemid 34493312)
12. • Kitazawa M, Vasilevko V, Cribbs DH, LaFerla FM. Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci. 2009;29:6132-41. Employing a strategy based on immunization with β-amyloid, these authors provide a more direct link between abnormal β-amyloid accumulation/deposition and the non-immune-mediated disruption of muscle function in IBM.
13. Malicdan MC, Noguchi S, Hayashi YK, Nishino I. Muscle weakness correlates with muscle atrophy and precedes the development of inclusion body or rimmed vacuoles in the mouse model of DMRV/hIBM. Physiol Genomics. 2008;35:106-15.
14. Malicdan MC, Noguchi S, Nishino I. Autophagy in a mouse model of distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Autophagy. 2007;3:396-8. (Pubitemid 46986355)
15. Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet. 2010;19:1741-55.
16. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, Danning C, Wada R, Thompson C, Bahtiyar G, Craft J, Hooft Van Huijsduijnen R, Plotz P. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A. 2000;97:9209-14. (Pubitemid 30626699)
17. Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, Chang J, Dwivedi S, Mitsak M, Chen YW, Plotz P, Rosen A, Hoffman E, Raben N. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005;52:1824-35. (Pubitemid 40852891)
18. • Li CK, Knopp P, Moncrieffe H, Sing B, Shaw S, Nagaraju K, Varsani H, Gao B, Wedderburn LR. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol. 2009;175:1030-40. This work extends the model of inducible MHC I upregulation originally published by Nagaraju et al. [17], underscoring the temporal discordance between muscle weakness and muscle inflammation that reflects a primary role for "nonimmune" pathways in the pathogenesis of IIM.
19. • Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin- 17A. Arthritis Rheum. 2009;60:2505-12. This study highlights the proinflammatory effects of IL-6 in a model of CIM and suggests that IL-6-mediated pathways represent potential therapeutic targets.
20. Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol. 2006;176:9-15. (Pubitemid 44080332)
21. •• Allenbach Y, Solly S, Gregoire S, Dubourg O, Salomon B, Butler-Browne G, Musset L, Herson S, Klatzmann D, Benveniste O. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol. 2009;174:989-98. Using a number of approaches, including antibody-mediated blockade/removal of Tregs, these authors demonstrate a clear role for this Tcell subset in counterbalancing pathogenic effector cells in a model of CIM. Equally important, this work supports the therapeutic potential of polyclonal Treg administration.
22. Sugihara T, Sekine C, Nakae T, Kohyama K, Harigai M, Iwakura Y, Matsumoto Y, Miyasaka N, Kohsaka H. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum. 2007;56:1304-14. (Pubitemid 46608656)
23. Sugihara T, Okiyama N, Suzuki M, Kohyama K, Matsumoto Y, Miyasaka N, Kohsaka H. Definitive engagement of cytotoxic CD8 T cells in C protein-induced myositis, a murine model of polymyositis. Arthritis Rheum. 2010;62:3088-92.
24. Katsumata Y, Harigai M, Sugiura T, Kawamoto M, Kawaguchi Y, Matsumoto Y, Kohyama K, Soejima M, Kamatani N, Hara M. Attenuation of experimental autoimmune myositis by blocking ICOS-ICOS ligand interaction. J Immunol. 2007;179:3772-9.
25. Matsumoto Y, Kohyama K, Park IK, Nakajima M, Hiraki K. Characterization of pathogenic T cells and autoantibodies in C-protein-induced autoimmune polymyositis. J Neuroimmunol. 2007;190:90-100. (Pubitemid 47625615)
26. Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, Fertig N, Oury T, Vandersteen D, Clemens P, Camacho CJ, Weinberg A, Ascherman DP. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29:174-86. (Pubitemid 47393612)
27. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen L, Hartlein M, Kron M, Yiadom K, Dwivedi S, Plotz PH, Oppenheim JJ. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196:781-91.
28. • SoejimaM, Kang EH, Gu X, Katsumata Y, Clemens PR, Ascherman DP. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum. 2011;63:479-87. This work demonstrates the capacity of a known autoantigen, HRS, to directly promote muscle inflammation through activation of innate immune responses that bypass the requirement for TCR signaling.